Sermorelin is a synthetic analog of growth hormone-releasing hormone, built from the first 29 amino acids of the 44-amino-acid endogenous peptide. Those 29 residues are the shortest fragment that retains full biological activity of GHRH, which is why the molecule exists in this form rather than as the complete sequence. It is one of the most extensively characterized growth hormone secretagogues in the literature, and it occupies a specific position in that literature: it acts one step upstream of growth hormone itself.
Mechanism: the receptor, not the hormone
Sermorelin binds the pituitary GHRH receptor, a G protein-coupled receptor with seven membrane-spanning domains expressed on somatotroph cells of the anterior pituitary. Receptor occupancy activates downstream signaling, including potent activation of the MAP kinase pathway in somatotrophs, and the cell responds by synthesizing and releasing its own growth hormone.
That distinction carries the weight of most sermorelin research. Exogenous growth hormone replaces the hormone. A GHRH analog instructs the gland to make it. The difference is not academic, because the pituitary sits inside a regulatory loop that exogenous hormone bypasses entirely.
Why the feedback loop matters to study design
Growth hormone release is pulsatile, not continuous, and it is restrained by somatostatin acting as the opposing arm of hypothalamic control. Because sermorelin works through the receptor rather than around it, somatostatin tone still applies. Research groups have used this property deliberately: it constrains the magnitude of the response and preserves the pulse architecture, which makes the model closer to endogenous physiology than a bolus of recombinant hormone.
The practical consequence for study design is that a GHRH analog cannot drive growth hormone past what the gland is capable of producing. A depleted or non-responsive somatotroph population produces a blunted response, and that blunting is itself the measurement. This is the basis for the compound’s long-standing use as a pituitary function probe rather than as a hormone substitute.
The somatopause literature
Growth hormone output declines progressively with age, a pattern described in the endocrine literature as somatopause. This decline is the reason a GHRH analog became interesting to aging researchers in the first place: if the somatotroph population remains responsive but under-stimulated, the deficit is one of signal rather than capacity.
Research in older cohorts has examined whether restoring GHRH signaling changes body composition, bone mineral density, sleep architecture, and recovery markers. Read that literature carefully and the picture is uneven. Effects on measured GH and IGF-1 are consistent and well replicated. Downstream effects on composition and function are smaller, more variable between studies, and heavily dependent on cohort age, baseline pituitary reserve, and study duration. The signal is real at the hormone level. It is considerably less clean at the outcome level.
Sleep architecture
Growth hormone secretion is predominantly nocturnal and tied to slow-wave sleep, which makes sleep both an input and an output in GH research and creates an interpretive problem. A compound that raises nocturnal GH may do so because it improved slow-wave sleep, or it may raise GH and affect sleep as a consequence, and separating those directions requires polysomnography rather than hormone assays alone.
Sermorelin sits on the favorable side of this comparison within the secretagogue class. Growth hormone releasing peptides acting at the ghrelin receptor do not behave uniformly here. Hexarelin, for instance, has been documented to decrease slow-wave sleep while raising GH, ACTH, cortisol and prolactin overnight. A GHRH analog and a ghrelin receptor agonist are not interchangeable tools even where both raise growth hormone.
Regulatory history, stated completely
Sermorelin acetate was approved by FDA as Geref, first in 1990 and again in 1997 for a second formulation, indicated for idiopathic growth hormone deficiency in children with growth failure and for evaluating somatotroph capacity to secrete growth hormone.
It is no longer an approved product. The manufacturer discontinued it in 2008, requested withdrawal of the applications in December of that year, and FDA withdrew approval effective 2009-06-18. The Federal Register determination on that withdrawal is the part worth knowing: the product was not withdrawn for reasons of safety or effectiveness. Sales had fallen as recombinant growth hormone took over the pediatric market. It was a commercial exit, not a regulatory one.
Anyone evaluating this compound should hold both halves of that history. “FDA approved” on its own is incomplete to the point of being misleading. “Withdrawn from the market” on its own implies a safety finding that the record does not support.
Where it sits against the other GHRH analogs
Sermorelin has a short circulating half-life, on the order of minutes, which closely mimics the endogenous GHRH pulse. CJC-1295 is the same class modified for duration. Without DAC it extends activity moderately. With DAC, a drug affinity complex binding albumin, it produces sustained elevation measured in days rather than minutes.
Those are three different experimental instruments, not three grades of the same one. Sustained receptor occupancy answers questions about total exposure. Short pulses answer questions about pulse architecture and receptor recovery. A study built to examine pulsatility that selects a DAC-modified analog has selected against its own endpoint.
Tesamorelin belongs to the same class and answers a fourth version of the question. Where sermorelin is the shortened natural sequence, tesamorelin is a stabilized full-length analog carrying an N-terminal modification that resists enzymatic breakdown, so it holds receptor engagement far longer than the endogenous pulse it derives from. It is also the only member of this class with a complete human regulatory record, approved as Egrifta. For a researcher, that record is the practical difference: the pharmacology of the class has been characterised in people for one of these compounds and not for the others.
What this literature does not establish
Worth stating plainly, because the marketing around this compound routinely overstates it.
The GH and IGF-1 response to GHRH analogs is well documented. Long-term outcome data in healthy adults is not. Most of the aging work involves modest cohorts, short durations, and surrogate endpoints rather than hard ones.
The pulsatility argument is mechanistically sound and largely theoretical in terms of demonstrated superiority. It is a reasonable inference from how the receptor behaves, not a proven clinical advantage over other approaches.
And responsiveness depends on the pituitary being able to respond. Where somatotroph reserve is genuinely diminished, the upstream signal has nothing to act on.
Handling and storage
Supplied as a lyophilized powder. Stored sealed at -20°C, protected from light. Peptides of this class are sensitive to mechanical stress, so vigorous agitation is avoided in standard laboratory handling.
Sources
- Regulation of the pituitary somatotroph cell by GHRH and its receptor
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
- Growth hormone-releasing hormone receptor (GHRH-R) and its signaling
- Federal Register: Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers
Related research
- Tesamorelin, the GHRH analog Etched carries
- Hexarelin: how a ghrelin-receptor agonist differs
- GH-axis compounds currently held
- The analytical record
- Research library
For in vitro research use only. Not for human or veterinary use, therapeutic, or diagnostic purposes.